S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Tuesday, 4/16/2024
Johnson & Johnson is as Cheap as it’s Going to Get
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Tuesday, 4/16/2024
Johnson & Johnson is as Cheap as it’s Going to Get
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Tuesday, 4/16/2024
Johnson & Johnson is as Cheap as it’s Going to Get
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
Silicon Motion Proves That AI in Motion Stays in Motion
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Tuesday, 4/16/2024
Johnson & Johnson is as Cheap as it’s Going to Get

Galera Therapeutics (GRTX) Competitors

$0.17
+0.02 (+13.33%)
(As of 04/16/2024 ET)

GRTX vs. VCNX, ATHE, VIRI, CMMB, KTTA, EFTR, BNOX, CLVR, ASLN, and PCSA

Should you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Vaccinex (VCNX), Alterity Therapeutics (ATHE), Virios Therapeutics (VIRI), Chemomab Therapeutics (CMMB), Pasithea Therapeutics (KTTA), eFFECTOR Therapeutics (EFTR), Bionomics (BNOX), Clever Leaves (CLVR), ASLAN Pharmaceuticals (ASLN), and Processa Pharmaceuticals (PCSA). These companies are all part of the "pharmaceutical preparations" industry.

Galera Therapeutics vs.

Vaccinex (NASDAQ:VCNX) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Comparatively, 6.9% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vaccinex has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500.

Vaccinex's return on equity of 0.00% beat Galera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
VaccinexN/A -2,667.31% -571.70%
Galera Therapeutics N/A N/A -137.47%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vaccinex
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Galera Therapeutics
1 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.75

Vaccinex received 73 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 60.00% of users gave Vaccinex an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote.

CompanyUnderperformOutperform
VaccinexOutperform Votes
123
60.00%
Underperform Votes
82
40.00%
Galera TherapeuticsOutperform Votes
50
54.35%
Underperform Votes
42
45.65%

In the previous week, Vaccinex and Vaccinex both had 2 articles in the media. Galera Therapeutics' average media sentiment score of 0.96 beat Vaccinex's score of 0.50 indicating that Vaccinex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vaccinex
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Galera Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vaccinex has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vaccinex$570K10.27-$20.25M-$100.86-0.05
Galera TherapeuticsN/AN/A-$59.08M-$1.41-0.12

Summary

Vaccinex beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Galera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRTX vs. The Competition

MetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.32M$6.51B$4.77B$7.49B
Dividend YieldN/A3.10%5.47%3.97%
P/E Ratio-0.127.97189.9015.37
Price / SalesN/A310.862,487.5987.76
Price / CashN/A19.9933.3029.61
Price / Book-0.075.504.674.27
Net Income-$59.08M$141.92M$101.24M$211.60M
7 Day Performance6.18%-5.30%-4.00%-3.76%
1 Month Performance-19.51%-5.70%-3.70%-2.68%
1 Year Performance-93.95%-1.97%11.41%5.86%

Galera Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VCNX
Vaccinex
0 of 5 stars
$7.18
+2.1%
N/A-94.8%$8.83M$570,000.00-0.0738Gap Up
ATHE
Alterity Therapeutics
3.4329 of 5 stars
$1.91
+1.6%
$7.00
+266.5%
-28.8%$8.92M$3.37M0.0011Short Interest ↓
VIRI
Virios Therapeutics
0.2138 of 5 stars
$0.46
+2.2%
N/A-34.2%$8.94MN/A-1.664Positive News
Gap Up
CMMB
Chemomab Therapeutics
1.8492 of 5 stars
$0.79
flat
$7.00
+786.1%
-59.2%$8.73MN/A-0.3720Short Interest ↑
KTTA
Pasithea Therapeutics
0 of 5 stars
$8.25
-2.4%
N/A-7.1%$8.59M$20,000.000.0015Gap Down
EFTR
eFFECTOR Therapeutics
1.5828 of 5 stars
$2.31
+8.5%
$24.00
+939.0%
-79.3%$8.52M$3.55M-0.1415Short Interest ↑
High Trading Volume
BNOX
Bionomics
1.4939 of 5 stars
$1.04
+1.0%
$9.00
+765.4%
-58.0%$8.49M$10,000.000.00N/AGap Up
CLVR
Clever Leaves
0.2546 of 5 stars
$4.81
-1.0%
N/A-54.2%$8.42M$17.42M-0.43400Positive News
Gap Up
ASLN
ASLAN Pharmaceuticals
2.6089 of 5 stars
$0.57
+3.6%
$11.33
+1,888.3%
-86.1%$9.32MN/A-0.1934Analyst Report
PCSA
Processa Pharmaceuticals
3.1809 of 5 stars
$2.91
-2.3%
N/A-84.6%$8.32MN/A-0.3915

Related Companies and Tools

This page (NASDAQ:GRTX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners